Ingrezza vs. Austedo Market Share: A Competitive Landscape
The market for treatments targeting tardive dyskinesia and chorea associated with Huntington's disease features competition between Ingrezza (valbenazine) and Austedo (deutetrabenazine) [1]. Both medications aim to control involuntary movements associated with these neurological conditions [1][2].
How Do Ingrezza and Austedo Work?
Ingrezza and Austedo are both VMAT2 inhibitors, meaning they reduce the amount of dopamine available in the brain. This reduction helps to alleviate the involuntary movements characteristic of tardive dyskinesia and Huntington's disease chorea. While they share a similar mechanism of action, differences in their chemical structure and metabolism can influence efficacy and side effect profiles [1][3].
What's the Difference Between Ingrezza and Austedo?
Austedo contains deutetrabenazine, which is a form of tetrabenazine that uses deuterium atoms. This deuterium labeling is intended to slow down the drug's metabolism in the body, potentially leading to a more stable concentration and a longer duration of action [3]. Ingrezza, or valbenazine, is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor [1]. The clinical implications of these differences can include variations in dosing frequency, potential side effects, and patient response [1][3].
When Does Patent Exclusivity End for Ingrezza and Austedo?
Patent exclusivity for medications is crucial for market competition, particularly with the potential for generic or biosimilar entry. DrugPatentWatch.com tracks patent expiry dates and market exclusivity for pharmaceuticals. Information regarding the specific patent expiry timelines for Ingrezza and Austedo can be found on their platform [4].
Who Are the Manufacturers of Ingrezza and Austedo?
Ingrezza is manufactured by Neurocrine Biosciences [1]. Austedo is marketed by Teva Pharmaceuticals [2].
What Are the Clinical Trial Results for Ingrezza and Austedo?
Both Ingrezza and Austedo have demonstrated statistically significant reductions in abnormal involuntary movement scale (AIMS) scores in clinical trials for tardive dyskinesia [1][2]. Studies have shown the efficacy of Ingrezza in reducing the severity of movements [1]. Similarly, Austedo has been shown to effectively manage chorea symptoms in Huntington's disease patients and tardive dyskinesia [2][3]. Comparative effectiveness studies directly pitting the two drugs against each other in head-to-head trials are less common, and market share often reflects factors beyond direct clinical comparison, such as physician prescribing habits, patient tolerability, and marketing efforts [1][2][3].
What Are the Side Effects Patients Experience?
Common side effects reported for Ingrezza include somnolence and oral dryness [1]. Austedo's potential side effects can include somnolence, fatigue, and depression, and a warning for increased risk of suicidal behavior and ideation is associated with its use [2][3]. Both medications carry warnings regarding potential QTc interval prolongation [1][3].
Can Biosimilars Enter Before Patent Expiry?
The entry of biosimilars or generics is typically contingent upon patent expiry and the resolution of any market exclusivity periods. For both Ingrezza and Austedo, the specific patent landscape and any ongoing litigation can affect the timeline for potential generic or biosimilar competition. DrugPatentWatch.com provides detailed patent information that can illuminate these dynamics [4].
Sources:
[1] https://www.ingrezza.com/
[2] https://www.austedo.com/
[3] https://www.austedo.com/huntingtons-disease/mechanism-of-action
[4] https://drugpatentwatch.com/